Compare Crispr Therapeutics AG (CRSP) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Logitech International SA — how do they compare? Crispr Therapeutics AG trades at $53.9 (market cap $5.23B), while Logitech International SA trades at $101.81 (market cap $14.96B). The key difference: Logitech International SA is far larger — about 2.9× Crispr Therapeutics AG's market cap, and Logitech International SA pays a 1.64% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | LOGI | |
|---|---|---|
Market Cap | $5.23B | $14.96B |
Sector | Health | Technology |
52-Week High | $76.78 | $126.69 |
52-Week Low | $44.34 | $85.84 |
Enterprise Value | $3.65B | $13.30B |
Dividend Yield | — | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Logitech (LOGI) trades at $104.87, down 1.37% on the day, with a neutral technical signal and mixed analyst sentiment. Recent Q1 2027 earnings beat estimates with EPS of $1.85 versus $1.26 expected, driven by tariff refunds and premium demand, though a key supplier shutdown clouds near-term outlook. Fundamentals show strong profitability with a 16.28% net margin and 35.29% ROE, while valuation metrics like a P/E of 19.03 appear reasonable. The stock faces resistance near $109, with support at $104.
The outlook is cautiously optimistic given solid earnings momentum and margin expansion, but supply chain disruptions pose a near-term risk. Upside to the $109.75 consensus price target offers potential, though investor sentiment is divided amid operational uncertainties. Key risks include supplier dependency and competitive pressures in the tech peripherals market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
